Drug development faces challenges due to incomplete, outdated, and difficult-to-compile safety information regarding drug targets. Manual safety assessments are time-consuming, require specialized expertise, and struggle to keep pace with the volume of available data, potentially leading to overlooked safety risks.

Sable Bio offers a platform that leverages artificial intelligence to provide comprehensive safety intelligence for drug targets, consolidating data from clinical, genetic, experimental, and textual sources. The platform delivers quantified risk evaluations and recommended mitigations tailored to specific modalities and modes of action. By offering up-to-date and easily digestible safety information, Sable Bio enables more efficient and informed decision-making in drug development, reducing the likelihood of safety-related failures in clinical trials. The platform's AI-augmented information extraction and curation, combined with customized toxicology-focused ontologies, ensures comprehensive safety coverage.

Individual target safety assessment tailored to chosen modality and mode of action

Target selection ranking based on safety risks associated with the chosen modality

Quantified and interpretable probability scores for safety assessments

Recommended actions and mitigations for identified safety risks, including assays and experimental validations

Expansions by mechanism, target similarity, or potential off-target effects for less-studied targets

Flexible report configuration with experimental data integration

Secure addition of proprietary experimental, clinical, or text data

API access for programmatic access to reports and scores

Sable Bio's primary customers are drug discovery teams and pharmaceutical companies seeking to improve target safety assessment and reduce the risk of clinical trial failures.